CO2020009106A2 - Derivados de tiofeno no condensados y sus usos - Google Patents
Derivados de tiofeno no condensados y sus usosInfo
- Publication number
- CO2020009106A2 CO2020009106A2 CONC2020/0009106A CO2020009106A CO2020009106A2 CO 2020009106 A2 CO2020009106 A2 CO 2020009106A2 CO 2020009106 A CO2020009106 A CO 2020009106A CO 2020009106 A2 CO2020009106 A2 CO 2020009106A2
- Authority
- CO
- Colombia
- Prior art keywords
- thiophene derivatives
- condensed thiophene
- diseases
- condensed
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305134 | 2018-02-08 | ||
| PCT/EP2019/053081 WO2019154956A1 (en) | 2018-02-08 | 2019-02-08 | Non-fused thiophene derivatives and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020009106A2 true CO2020009106A2 (es) | 2020-10-30 |
Family
ID=61283124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0009106A CO2020009106A2 (es) | 2018-02-08 | 2020-07-24 | Derivados de tiofeno no condensados y sus usos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11767316B2 (https=) |
| EP (2) | EP3749649A1 (https=) |
| JP (1) | JP7399110B2 (https=) |
| KR (2) | KR102871188B1 (https=) |
| CN (1) | CN111936471B (https=) |
| AU (1) | AU2019219123B2 (https=) |
| BR (1) | BR112020015743A2 (https=) |
| CA (1) | CA3087830A1 (https=) |
| CO (1) | CO2020009106A2 (https=) |
| EA (1) | EA202091897A1 (https=) |
| IL (1) | IL275893B2 (https=) |
| MX (1) | MX2020007917A (https=) |
| PH (1) | PH12020551175A1 (https=) |
| SG (1) | SG11202006723SA (https=) |
| WO (2) | WO2019154953A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020015743A2 (pt) | 2018-02-08 | 2020-12-15 | Enyo Pharma | Derivados de tiofeno não fundido e seus usos |
| MX2020007918A (es) | 2018-02-08 | 2020-12-03 | Enyo Pharma | Derivados fusionados de tiofeno y sus usos. |
| CN114555577A (zh) * | 2019-10-17 | 2022-05-27 | 埃尼奥制药公司 | 用于治疗门静脉炎症和纤维化的噻吩衍生物 |
| CA3164134A1 (en) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| WO2022020714A1 (en) * | 2020-07-24 | 2022-01-27 | Inipharm, Inc. | Thiophene hsd17b13 inhibitors and uses thereof |
| EP4192448A1 (en) | 2020-08-05 | 2023-06-14 | ENYO Pharma | Thiophen compounds for use in the treatment of renal fibrosis |
| CN116670118B (zh) | 2020-11-13 | 2026-02-06 | 伊尼制药公司 | 二氯苯酚hsd17b13抑制剂及其用途 |
| CN112851633B (zh) * | 2021-01-19 | 2021-12-07 | 上海应用技术大学 | 一种2-氨基噻吩类神经氨酸酶抑制剂及其制备方法与应用 |
| EP4323362B1 (en) | 2021-04-16 | 2025-05-07 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| WO2024037604A1 (zh) * | 2022-08-17 | 2024-02-22 | 彭光浩 | 基于多种碳氮代谢途径的分枝杆菌、分离方法及用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| DE10359791A1 (de) * | 2003-12-19 | 2005-07-21 | Bayer Healthcare Ag | Substituierte Thiophene |
| JP5411141B2 (ja) * | 2007-09-10 | 2014-02-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| US8389567B2 (en) | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US7906553B2 (en) * | 2008-08-27 | 2011-03-15 | Calcimedica, Inc. | Substituted thiophene modulators of intracellular calcium |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2011097607A1 (en) * | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| US20150126519A1 (en) * | 2012-03-20 | 2015-05-07 | Fred Hutchinson Cancer Research Center | Antibiotic compounds and compositions, and methods for identification thereof |
| EP2679591A1 (en) * | 2012-06-29 | 2014-01-01 | Poxel | Thienopyridone derivatives useful as activators of AMPK |
| WO2015187827A1 (en) | 2014-06-03 | 2015-12-10 | The Trustees Of The University Of Pennsylvania | Novel effective antiviral compounds and methods using same |
| TW201607930A (zh) | 2014-07-18 | 2016-03-01 | 百濟神州有限公司 | 作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途 |
| KR20190098204A (ko) | 2016-12-29 | 2019-08-21 | 엔요 파마 | 항바이러스제로서의 티오펜 유도체 |
| BR112020015743A2 (pt) | 2018-02-08 | 2020-12-15 | Enyo Pharma | Derivados de tiofeno não fundido e seus usos |
| MX2020007918A (es) | 2018-02-08 | 2020-12-03 | Enyo Pharma | Derivados fusionados de tiofeno y sus usos. |
| WO2019154958A1 (en) | 2018-02-08 | 2019-08-15 | Enyo Pharma | Use of modulators of neet proteins for the treatment of infection |
-
2019
- 2019-02-08 BR BR112020015743-0A patent/BR112020015743A2/pt not_active IP Right Cessation
- 2019-02-08 EP EP19703332.7A patent/EP3749649A1/en not_active Withdrawn
- 2019-02-08 EP EP19703333.5A patent/EP3749650A1/en active Pending
- 2019-02-08 EA EA202091897A patent/EA202091897A1/ru unknown
- 2019-02-08 JP JP2020565534A patent/JP7399110B2/ja active Active
- 2019-02-08 CN CN201980012287.0A patent/CN111936471B/zh active Active
- 2019-02-08 IL IL275893A patent/IL275893B2/en unknown
- 2019-02-08 CA CA3087830A patent/CA3087830A1/en active Pending
- 2019-02-08 SG SG11202006723SA patent/SG11202006723SA/en unknown
- 2019-02-08 WO PCT/EP2019/053077 patent/WO2019154953A1/en not_active Ceased
- 2019-02-08 US US16/967,744 patent/US11767316B2/en active Active
- 2019-02-08 KR KR1020247027773A patent/KR102871188B1/ko active Active
- 2019-02-08 US US16/967,753 patent/US11840527B2/en active Active
- 2019-02-08 AU AU2019219123A patent/AU2019219123B2/en not_active Ceased
- 2019-02-08 KR KR1020207023770A patent/KR20200141026A/ko not_active Ceased
- 2019-02-08 WO PCT/EP2019/053081 patent/WO2019154956A1/en not_active Ceased
- 2019-02-08 MX MX2020007917A patent/MX2020007917A/es unknown
-
2020
- 2020-07-24 CO CONC2020/0009106A patent/CO2020009106A2/es unknown
- 2020-08-03 PH PH12020551175A patent/PH12020551175A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210040059A1 (en) | 2021-02-11 |
| US11840527B2 (en) | 2023-12-12 |
| AU2019219123B2 (en) | 2022-12-08 |
| JP2021514385A (ja) | 2021-06-10 |
| KR20200141026A (ko) | 2020-12-17 |
| KR102871188B1 (ko) | 2025-10-15 |
| IL275893B2 (en) | 2024-08-01 |
| MX2020007917A (es) | 2020-10-28 |
| EP3749650A1 (en) | 2020-12-16 |
| WO2019154953A1 (en) | 2019-08-15 |
| AU2019219123A1 (en) | 2020-08-06 |
| IL275893B1 (en) | 2024-04-01 |
| EP3749649A1 (en) | 2020-12-16 |
| CN111936471A (zh) | 2020-11-13 |
| KR20240131460A (ko) | 2024-08-30 |
| US11767316B2 (en) | 2023-09-26 |
| PH12020551175A1 (en) | 2021-06-07 |
| BR112020015743A2 (pt) | 2020-12-15 |
| EA202091897A1 (ru) | 2020-10-27 |
| CA3087830A1 (en) | 2019-08-15 |
| WO2019154956A1 (en) | 2019-08-15 |
| JP7399110B2 (ja) | 2023-12-15 |
| SG11202006723SA (en) | 2020-08-28 |
| IL275893A (en) | 2020-08-31 |
| CN111936471B (zh) | 2024-10-29 |
| US20200369655A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020009106A2 (es) | Derivados de tiofeno no condensados y sus usos | |
| AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| CL2019002461A1 (es) | Arn terapéutico. | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
| MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
| MX2020007918A (es) | Derivados fusionados de tiofeno y sus usos. | |
| MX365574B (es) | 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas. | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| CL2018000914A1 (es) | Ácido (s) -3-amino-4- (difluorometilenil) ciclopent-1-en-1-carboxílico, y compuestos relacionados como inactivadores de gaba aminotransferasa para el tratamiento de epilepsia, adicción y carcinoma hepatocelular | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| ECSP17064695A (es) | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 | |
| UY36126A (es) | ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?. | |
| MX2021006943A (es) | Anelosomas para suministrar modalidades terapéuticas secretadas. | |
| MX2018012902A (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
| CU24603B1 (es) | Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios | |
| MX2017002013A (es) | Polimorfos de selinexor. | |
| ECSP20061378A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma | |
| MX2017005861A (es) | Metodos para el control transcripcional objetivo en regiones del super mejorador. | |
| UY36868A (es) | Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5) |